High-Grade Glioma - Pipeline Review, H2 2016 - Overview, Comparative Analysis & Pipeline Products Glance - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "High-Grade Glioma - Pipeline Review, H2 2016" report to their offering.

High-grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated appetite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. High-Grade Glioma Overview
  3. Therapeutics Development
  4. Pipeline Products for High-Grade Glioma - Overview
  5. Pipeline Products for High-Grade Glioma - Comparative Analysis
  6. High-Grade Glioma - Therapeutics under Development by Companies
  7. High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes
  8. High-Grade Glioma - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. High-Grade Glioma - Products under Development by Companies
  13. High-Grade Glioma - Products under Investigation by Universities/Institutes
  14. High-Grade Glioma - Companies Involved in Therapeutics Development

Companies Mentioned:

  • Advenchen Laboratories LLC
  • AngioChem Inc
  • Arog Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Athenex Inc
  • Bayer AG
  • BTG Plc
  • Cavion LLC
  • CBT Pharmaceuticals Inc
  • DelMar Pharmaceuticals Inc
  • Merrimack Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Nektar Therapeutics
  • Novartis AG
  • Sanofi
  • Sumitomo Dainippon Pharma Co Ltd
  • Targepeutics Inc
  • Tocagen Inc
  • Virttu Biologics Ltd
  • ZIOPHARM Oncology Inc

For more information about this report visit http://www.researchandmarkets.com/research/9xqfdh/highgrade_glioma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs